HitGen Inc. (SHA:688222)

China · Delayed Price · Currency is CNY

29.45

-0.81 (-2.68%)

At close: Feb 13, 2026

Revenue by Product

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017
Deoxyribonucleic Acid Encoded Compound Library Screening Service	97.57M
Fragment-based Drug Design/Structure-based Drug Design Research & Development Services	90.96M
Deoxyribonucleic Acid Encoded Compound Library Customization Service	84.69M
Chemical Synthesis Services	52.00M
New Drug Custom Development	19.48M
Compound Structure Intellectual Property Transfer Fee	10.21M
New Drug Research Equity Transfer	1.89M
New Drug Research Equity Transfer Growth	-88.90%
Other	14.27M

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017
United States	249.87M
United States Growth	52.21%
China	62.75M
China Growth	-8.40%
Denmark	18.80M
Denmark Growth	-8.13%
United Kingdom	14.57M
United Kingdom Growth	33.50%
Japan	9.59M
Japan Growth	103.57%
South Korea	5.09M
South Korea Growth	-31.03%
France	4.62M
France Growth	-88.72%
Other Countries	3.76M
Other Countries Growth	1.29%
Germany	1.49M
Germany Growth	-76.03%
Other	780.75K
Other Growth	-70.11%